SCHEMBL2855475

SCHEMBL2855475

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2Cl)cc1Oc1ccc2nc(NC(=O)CCl)sc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.41
BRAF P15056 5/20 0.41
ROCK2 O75116 1/20 0.39
KIT P10721 2/20 0.39
FLT1 P17948 2/20 0.39
PDGFRB P09619 1/20 0.39
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
PTGES O14684 3/20 0.38
BTK Q06187 1/20 0.37
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAP3K7 O43318 1/20 0.36
MAP4K2 Q12851 1/20 0.36
MAPK14 Q16539 1/20 0.36
MAP3K20 Q9NYL2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853585 0.94 KDR (0.39) KDRBRAFROCK2KITFLT1
SCHEMBL2862228 0.92 KDR (0.47) KDRBRAFKITFLT1PDGFRB
SCHEMBL2855441 0.89 KDR (0.51) KDRBRAFKITFLT1PDGFRB
SCHEMBL2858590 0.88 ALDH1A1 (0.41) KDRBRAFKITFLT1PDGFRB
SCHEMBL2853460 0.88 KDR (0.47) KDRBRAFKITFLT1PDGFRB
SCHEMBL2853807 0.87 RAF1 (0.40) KDRBRAFFLT1MAPTLMNA
SCHEMBL2855913 0.85 BTK (0.50) KDRBRAFKITPDGFRBBTK
SCHEMBL2851200 0.80 KDR (0.50) KDRBRAFKITFLT1PDGFRB
SCHEMBL2875503 0.79 KDR (0.55) KDRBRAFKITFLT1PDGFRB
SCHEMBL2861306 0.78 BRAF (0.50) KDRBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 KDR 983/4885BRAF 1/4885ROCK2 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.